Union Acquisition II (PROC)
(Delayed Data from NSDQ)
$2.79 USD
+0.03 (1.09%)
Updated May 28, 2024 03:59 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Procaps Group, S.A. (PROC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.50 | $4.50 | $4.50 | 63.04% |
Price Target
Only one analyst offered a short-term price target of $4.50 for Procaps Group, S.A. This represents an increase of 63.04% from the last closing price of $2.76.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Hold-equivalent recommendation for Procaps Group, S.A. This translates to an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 3.00 a month ago based on just one recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/16/2024 | Brookline Capital Markets | Kemp Dolliver | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 1 |
Average Target Price | $4.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | NA |